Genomics of noninvasive disease

Thoma, Clemens

doi:10.1038/nrurol.2017.207

Research Highlight
Published: 05 December 2017

Bladder cancer

Genomics of noninvasive disease

Clemens Thoma

Nature Reviews Urology volume 15, page 1 (2018)Cite this article

614 Accesses
1 Citations
5 Altmetric
Metrics details

Subjects

Access through your institution

Buy or subscribe

Noninvasive bladder cancer (stage Ta) can be separated into two genomic subtypes, according to a new analysis published in Cancer Cell. The subtypes can be distinguished by deletion of 9q, upregulation of mechanistic target of rapamycin complex 1 (mTORC1) signalling, and an altered metabolic profile. In addition, the study revealed that mutations in the lysine-specific demethylase 6A (KDM6A) are more frequent in Ta tumours from women than in those from men.

Stage Ta tumours are the largest group of diagnosed non-muscle-invasive bladder cancers (NMIBC). The risk of progression for these tumours is low but local disease recurrence is frequent, leading to the highest overall treatment costs for bladder cancer compared with other cancers. Hence, an improved understanding of the molecular composition of these tumours is required to advance patient stratification and approaches for localized treatment.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Hurst, C. D. et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32, 701–715.e7 (2017)10.1016/j.ccell.2017.08.005
Article CAS PubMed PubMed Central Google Scholar

Download references

Authors